Michal Shteinberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2601458/publications.pdf

Version: 2024-02-01

46 papers

2,235 citations

331670 21 h-index 223800 46 g-index

46 all docs

46 docs citations

46 times ranked

2235 citing authors

#	Article	IF	Citations
1	Cystic fibrosis. Lancet, The, 2021, 397, 2195-2211.	13.7	316
2	Characterization of the "Frequent Exacerbator Phenotype―in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1410-1420.	5.6	215
3	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2021, 57, 2100048.	6.7	152
4	The independent contribution of <i>Pseudomonas aeruginosa</i> infection to long-term clinical outcomes in bronchiectasis. European Respiratory Journal, 2018, 51, 1701953.	6.7	150
5	The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. European Respiratory Journal, 2018, 52, 1800328.	6.7	138
6	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Research, 2016, 2, 00081-2015.	2.6	133
7	Phosphorylation of the Cyclosome Is Required for Its Stimulation by Fizzy/cdc20. Biochemical and Biophysical Research Communications, 1999, 260, 193-198.	2.1	127
8	Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. The Lancet Global Health, 2019, 7, e1269-e1279.	6.3	116
9	Phosphorylation of Cdc20/Fizzy Negatively Regulates the Mammalian Cyclosome/APC in the Mitotic Checkpoint. Biochemical and Biophysical Research Communications, 2000, 271, 299-304.	2.1	109
10	Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respiratory Medicine,the, 2022, 10, 298-306.	10.7	70
11	Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease. European Respiratory Review, 2020, 29, 190112.	7.1	69
12	Standardised classification of the aetiology of bronchiectasis using an objective algorithm. European Respiratory Journal, 2017, 50, 1701289.	6.7	63
13	Clinical and biological characterization of macroprolactinemia with and without prolactin-lgG complexes. European Journal of Endocrinology, 2003, 149, 201-207.	3.7	59
14	Binding of Activated Cyclosome to p13. Journal of Biological Chemistry, 1997, 272, 18051-18059.	3.4	52
15	Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age. Journal of Cystic Fibrosis, 2019, 18, 525-529.	0.7	43
16	Role of Suc1 in the Activation of the Cyclosome by Protein Kinase $Cdk1/Cyclin\ B$. Biochemical and Biophysical Research Communications, 1999, 257, 12-18.	2.1	42
17	Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 776-782.	0.7	32
18	Prevalence, risk factors and prognosis of nontuberculous mycobacterial infection among people with bronchiectasis: aÂpopulation survey. European Respiratory Journal, 2018, 51, 1702469.	6.7	29

#	Article	IF	CITATIONS
19	Upper airway involvement in bronchiectasis is marked by early onset and allergic features. ERJ Open Research, 2018, 4, 00115-2017.	2.6	28
20	The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) ERS Clinical Research Collaboration. European Respiratory Journal, 2018, 52, 1802074.	6.7	26
21	Fertility and Pregnancy in Cystic Fibrosis. Chest, 2021, 160, 2051-2060.	0.8	26
22	Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2022, 60, 2200803.	6.7	22
23	Baseline Cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression. Journal of Cystic Fibrosis, 2021, 20, 388-394.	0.7	21
24	Clinical Characteristics and Outcomes of Patients with Clinically Unsuspected Pulmonary Embolism versus Patients with Clinically Suspected Pulmonary Embolism. Respiration, 2012, 84, 492-500.	2.6	19
25	lvacaftor for the p.Ser549Arg (S549R) gating mutation – The Israeli experience. Respiratory Medicine, 2017, 131, 225-228.	2.9	19
26	Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study. ERJ Open Research, 2018, 4, 00022-2018.	2.6	19
27	Decreased Fecal Calprotectin Levels in Cystic Fibrosis Patients After Antibiotic Treatment for Respiratory Exacerbation. Journal of Pediatric Gastroenterology and Nutrition, 2019, 68, 282-284.	1.8	19
28	ROSE: radiology, obstruction, symptoms and exposure – a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group. ERJ Open Research, 2021, 7, 00399-2021.	2.6	19
29	Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor. Journal of Cystic Fibrosis, 2017, 16, 45-48.	0.7	12
30	Radiologic Characteristics of Non-tuberculous Mycobacteria Infection in Patients with Bronchiectasis. Lung, 2020, 198, 715-722.	3.3	11
31	Is bronchiectasis really a disease?. European Respiratory Review, 2020, 29, 190051.	7.1	10
32	Calcium carbonate mineralization is essential for biofilm formation and lung colonization. IScience, 2022, 25, 104234.	4.1	9
33	What is important for people with nontuberculous mycobacterial disease? An EMBARC-ELF patient survey. ERJ Open Research, 2021, 7, 00807-2020.	2.6	8
34	Diagnosis and Evaluation of Bronchiectasis. Clinics in Chest Medicine, 2022, 43, 7-22.	2.1	7
35	Bronchiectasis Exacerbations: Definitions, Causes, and Acute Management. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 595-605.	2.1	6
36	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. Annals of the American Thoracic Society, 2021, 18, 1316-1325.	3.2	6

3

#	Article	IF	CITATIONS
37	Novel non-invasive early detection of lung cancer using liquid immunobiopsy metabolic activity profiles. Cancer Immunology, Immunotherapy, 2018, 67, 1135-1146.	4.2	5
38	Survival dynamics of cystic fibrosis-related Gram-negative bacterial pathogens (Pseudomonas) Tj ETQq 000 rgBT and Health, 2015, 13, 773-776.	Overlock 2.6	10 Tf 50 707 4
39	New insights into immunological responses to infection in bronchiectasis. European Respiratory Journal, 2019, 53, 1802395.	6.7	4
40	Recommendations for travelling with bronchiectasis: a joint ELF/EMBARC/ERN-Lung collaboration. ERJ Open Research, 2019, 5, 00113-2019.	2.6	4
41	Clinical characteristics and outcomes of patients with Escherichia coli in airway samples. Clinical Respiratory Journal, 2020, 14, 205-213.	1.6	4
42	Desensitization therapy in a patient with furosemide allergy. European Journal of Internal Medicine, 2007, 18, 69-70.	2.2	3
43	â€~Go for it, dream big, work hard and persist': A message to the next generation of CF leaders in recognition of International Women's Day 2020. Journal of Cystic Fibrosis, 2020, 19, 184-193.	0.7	3
44	Crohn's Disease with Atypical Extra-Intestinal Manifestations Developing Under Treatment with Vedolizumab. European Journal of Case Reports in Internal Medicine, 2019, 8, 002265.	0.4	3
45	4-week daily airway clearance using oscillating positive-end expiratory pressure <i>versus</i> autogenic drainage in bronchiectasis patients: a randomised controlled trial. ERJ Open Research, 2021, 7, 00426-2021.	2.6	2
46	Exploring factors associated with acquisition and chronicity of infection in bronchiectasis: A population-based study. Respiratory Medicine, 2021, 185, 106487.	2.9	1